Bristol Myers Squibb Company $BMY Holdings Trimmed by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,940,669 shares of the biopharmaceutical company’s stock after selling 216,303 shares during the period. Russell Investments Group Ltd. owned approximately 0.14% of Bristol Myers Squibb worth $136,140,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Trifecta Capital Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $25,000. REAP Financial Group LLC increased its holdings in shares of Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 428 shares in the last quarter. Accent Capital Management LLC bought a new position in shares of Bristol Myers Squibb in the first quarter valued at $33,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Bristol Myers Squibb by 66.0% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 231 shares during the last quarter. Finally, GKV Capital Management Co. Inc. bought a new stake in shares of Bristol Myers Squibb during the 1st quarter worth $36,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on BMY shares. Citigroup reduced their target price on Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating for the company in a report on Monday, November 17th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Scotiabank started coverage on shares of Bristol Myers Squibb in a research report on Thursday, November 13th. They issued a “sector perform” rating and a $45.00 price target for the company. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Four research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $54.42.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $49.05 on Wednesday. The business’s 50-day moving average is $45.37 and its 200-day moving average is $46.58. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The company has a market capitalization of $99.84 billion, a price-to-earnings ratio of 19.78, a P/E/G ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the business earned $1.80 EPS. The company’s revenue for the quarter was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.1%. The ex-dividend date was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 83.78%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.09% of the company’s stock.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.